8-K: Apimeds Settles Disputes, Restructures Operations

Apimeds Pharmaceuticals US, Inc. has entered into a settlement and mutual release agreement to resolve outstanding disputes, restructure its operations, and establish new governance for its subsidiaries.

Summary

• Apimeds Pharmaceuticals US, Inc. (the Company) has entered into a Confidential Settlement and Mutual Release Agreement (the Settlement Agreement) dated April 24, 2026, to resolve disputes arising from a prior Merger Agreement.
• The agreement involves Apimeds Pharmaceuticals US, Inc., MindWave Innovations Inc, Erik Emerson, Lokahi Therapeutics, Inc., Inscobee Inc., and Apimeds Inc.
• Key terms include Lokahi Therapeutics retaining the Apitox program assets and contributing $4,000,000 (Working Capital Contribution) to the Company.
• A new subsidiary, Newco, will be formed and spun off within 12 months, with 10% of net financing proceeds allocated to it and 90% to MindWave.
• The agreement also addresses corporate governance, including board composition changes and the appointment of new officers.
• An irrevocable proxy has been granted by the Inscobee Parties to Dr. Vin Menon and Captain Sandeep Singh Yadav to vote on specific proposals.
• A Forbearance Agreement with Alto Opportunity Master Fund, SPC, provides a period of forbearance on existing defaults through June 30, 2026, contingent on meeting specific conditions.
• Mutual releases of claims are included, effective upon Lokahi's Working Capital Contribution.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously optimistic development. While the settlement resolves disputes and outlines a path forward, significant risks and stringent conditions remain, particularly concerning NYSE compliance and financial stability.

Positives

• Resolution of outstanding disputes, avoiding costly litigation.
• Restructuring of operations with the formation and planned spin-off of Newco.
• Secured a $4,000,000 Working Capital Contribution from Lokahi.
• Lokahi Therapeutics will retain the Apitox program, potentially allowing for focused development.
• An irrevocable proxy has been granted, providing clarity on voting for key proposals.
• A forbearance agreement with a key investor provides a defined period to meet critical conditions.
• Mutual releases of claims aim to reset relationships and prevent future litigation.
• The settlement aims to clarify corporate governance and board composition.

Negatives

• The company faces significant hurdles to regain compliance with NYSE listing requirements by June 30, 2026.
• Failure to meet forbearance conditions by June 30, 2026, could lead to the Investor exercising remedies.
• The company must file its Form 10-K by April 30, 2026, and obtain a clean audit opinion, which is a critical deadline.
• The settlement involves a complex restructuring and spin-off of a new subsidiary, which carries execution risk.
• The company's common stock remains halted on NYSE American, indicating ongoing regulatory or compliance issues.
• The settlement is contingent on multiple conditions being met, creating uncertainty.
• The company has a history of defaults and breaches, as evidenced by the Forbearance Agreement.
• The settlement requires cooperation from all parties, and any breach could jeopardize the entire agreement.

Risks

• Failure to meet the April 30, 2026 deadline for filing the Form 10-K or obtaining a clean audit opinion could trigger a Merger Agreement unwind.
• Failure to cure all deficiencies and regain compliance with NYSE listing requirements by June 30, 2026, could lead to delisting.
• The Investor may exercise remedies if any of the Forbearance Conditions are not met by the specified deadlines.
• The spin-off of Newco within 12 months is subject to board approval and potential extensions, introducing timing uncertainty.
• The effectiveness of the proposed stock conversions and other proposals is contingent on NYSE approval.
• The settlement relies on the cooperation of multiple parties, and any dispute or failure to cooperate could unravel the agreement.
• The company's ability to secure future financing is implicitly linked to resolving its listing and compliance issues.
• The complex corporate restructuring and governance changes introduce operational and execution risks.

Future Outlook

The company aims to resolve its listing issues with NYSE American, complete proposed stock conversions and note approvals, and spin off its new subsidiary, Newco, within 12-24 months. The success of these initiatives is contingent on meeting strict deadlines and obtaining necessary approvals.

Management Comments

• Dr. Vin Menon continues to serve as Chief Executive Officer of the Company.
• Menon shall have final authority over actions of the Company and Mindwave, while the co-chief executive officer shall have final authority over Newco.
• Erik Emerson will continue as Lokahi's CEO and President, with no party other than Lokahi able to remove him.
• The settlement is not an admission of liability by any party.

Industry Context

StockSavvy.ai notes that this settlement is a critical step for Apimeds Pharmaceuticals US, Inc. to navigate significant corporate governance and financial distress. The resolution of disputes and restructuring efforts are common in companies facing delisting threats or significant operational challenges, aiming to stabilize operations and regain investor confidence.

Comparison to Industry Standards

• The timeline for curing NYSE listing deficiencies (by June 30, 2026) is aggressive and typical for companies under such pressure, requiring swift action on regulatory filings and corporate actions.
• The formation and spin-off of a new subsidiary (Newco) is a strategic move to isolate certain assets or operations, a practice seen in various industries to unlock value or streamline focus.
• The use of an irrevocable proxy to ensure voting alignment on key proposals is a mechanism employed to overcome shareholder disputes and facilitate necessary corporate actions, though it can also raise governance concerns if not balanced.
• The mutual release of claims is standard in settlement agreements to provide finality and prevent future litigation, a common practice across all industries undergoing significant corporate restructurings or dispute resolutions.

Management Changes

Corporate Governance

Legal Proceedings

• Erik Emerson to file a stipulation of dismissal without prejudice for the action filed against the Inscobee Parties in the U.S. District Court for the Southern District of New York (Lokahi Action) within five business days of the Effective Date. This dismissal converts to with prejudice on the 180th day if no breach by Inscobee Parties.
• Mutual releases of all claims arising from facts, acts, omissions, circumstances, events, or transactions occurring before the execution of the Settlement Agreement, subject to specific carve-outs (e.g., breach of agreement, fraud).

Related Party Transactions

• The settlement agreement resolves disputes arising from the Merger Agreement and related transactions involving Apimeds Pharmaceuticals US, Inc., MindWave Innovations Inc, Erik Emerson, Lokahi Therapeutics, Inc., Inscobee Inc., and Apimeds Inc.
• Lokahi Therapeutics, Inc. is to forgive all amounts previously advanced to the Company or its subsidiaries, including a $750,000 advance.
• The Company will distribute 51% of Lokahi's common stock to Erik Emerson upon payment of the Working Capital Contribution.
• Dr. Vin Menon is appointed CEO of the Company and will serve as Executive Chairman of MindWave's board post-closing.
• A co-CEO for the Company will be designated by the Inscobee Parties.

Stakeholder Impact

• Shareholders: The settlement aims to resolve disputes that have likely impacted share price and trading. The success of the NYSE listing application and future performance will be critical for shareholder value.
• Employees: Changes in management and board composition may lead to shifts in company direction and culture. The spin-off of Newco could also impact employee roles and responsibilities.
• Creditors: The Forbearance Agreement with the Investor (Alto Opportunity Master Fund) indicates existing debt and potential default events. The company's ability to meet forbearance conditions is crucial for creditors.
• Suppliers: The operational restructuring and potential spin-off of Newco could affect existing supplier relationships and contracts.

Next Steps

• Lokahi Therapeutics must make the $4,000,000 Working Capital Contribution within five business days of the Effective Date.
• The Company must form Newco within seven business days of the Effective Date.
• The Company must file its Annual Report on Form 10-K by April 30, 2026.
• The Company must cure all NYSE listing deficiencies and regain compliance by June 30, 2026.
• The Company must file its initial registration statement by May 10, 2026, and have it declared effective by June 30, 2026.
• The Company must appoint new independent directors to its board by June 30, 2026.
• The Inscobee Parties must amend their Schedule 13D filings within four business days of the Effective Date.
• A joint press release announcing the settlement must be issued within five business days of the Effective Date.

Key Dates

Recommendation

The settlement agreement is a necessary step to address significant corporate and financial challenges, including potential delisting. However, the company faces numerous critical deadlines and conditions that must be met to regain compliance and stabilize operations. The outcome remains highly uncertain, warranting a 'hold' recommendation until substantial progress is demonstrated.

Keywords

Settlement Agreement, Mutual Release, Merger Agreement, Corporate Governance, Forbearance Agreement, NYSE Listing, Subsidiary Spin-off, Lokahi Therapeutics